Analysts cite positive clinical trial progress as the key driver for reiterating the stock’s bullish outlook.
Guggenheim reaffirmed its Buy rating on EyePoint Pharmaceuticals (EYPT) following recent advancements in the company’s clinical trials. The firm highlighted progress in the development pipeline as a critical factor supporting the decision, though specific trial data was not disclosed in the update.
EyePoint’s stock has faced volatility amid broader biotech sector trends, with prior analyst ratings split between Buy and Hold. The reiteration follows a period of underperformance relative to peers, as investors await further trial readouts expected later this year.
Shares of EyePoint showed modest gains in pre-market trading following the announcement, reflecting cautious optimism among investors.